背景:研究发现BH3相互作用域死亡激动剂(BID)与多种肿瘤的发生发展密切相关。然而,肾透明细胞癌(ccRCC)的BID状况很少受到关注。所以,我们的目的是探讨BID在ccRCC中的作用。
方法:生存分析,ROC曲线,进行相关性分析和Cox回归分析,分析BID在ccRCC中的预后价值和临床相关性。在训练队列中构建风险预后模型,并在内测队列中进一步验证,ICGC队列,和GEO队列。使用转录组测序和临床标本的免疫组织化学染色来验证生物信息学分析的结果。GSEA,估计算法,CIBERSORT算法,ssGSEA,潮流得分,相关性和差异性分析BID对肿瘤微环境(TME)免疫浸润的影响。
结果:BID在ccRCC组织中高表达,通过临床标本的转录组测序和免疫组织化学染色进行了验证。BID高表达的患者预后较差。BID是ccRCC的独立预后因素。基于BID的预后模型可以准确预测不同队列患者的预后。此外,BID的表达水平与PD-1,LAG3和CTLA4等免疫调节分子密切相关.富集分析表明BID在免疫相关应答和癌症相关途径中显著富集。BID表达的改变介导了TME免疫浸润的不同特征。
结论:BID在ccRCC中高表达,是ccRCC预后的可靠生物标志物。它与TME密切相关,并可能成为ccRCC患者免疫治疗的潜在靶点。
BACKGROUND: Studies have found that BH3 interacting domain death agonist (
BID) is closely related to the occurrence and development of many kinds of tumors. However, little attention has been paid to the situation of BID in clear cell renal cell carcinoma (ccRCC). So, our aim was to explore the effect of
BID in ccRCC.
METHODS: Survival analysis, ROC curve, correlation analysis and Cox regression analysis were executed to analyze the prognostic value and clinical correlation of BID in ccRCC. The risk prognosis model was constructed in the training cohort and further validated in the internal testing cohort, ICGC cohort, and GEO cohort. Transcriptome sequencing and immunohistochemical staining of clinical specimens were used to validate the results of bioinformatics analysis. The GSEA, ESTIMATE algorithm, CIBERSORT algorithm, ssGSEA, TIDE score, correlation and difference analysis were used to analyze the effects of BID on immune infiltration in tumor microenvironment (TME).
RESULTS: BID was highly expressed in ccRCC tissues, which was verified by transcriptome sequencing and immunohistochemical staining of clinical specimens. Patients with high expression of
BID had a worse prognosis.
BID is an independent prognostic factor for ccRCC. The prognostic model based on BID can accurately predict the prognosis of patients in different cohorts. In addition, the expression levels of BID was closely related to immunomodulatory molecules such as PD-1, LAG3, and CTLA4. Enrichment analysis indicated that BID was significantly enriched in immune-related responses and cancer-related pathways. The change of
BID expression mediates different characteristics of immune infiltration in TME.
CONCLUSIONS: BID is highly expressed in ccRCC, which is a reliable biomarker of ccRCC prognosis. It is closely related to TME, and may be a potential target for immunotherapy in patients with ccRCC.